Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jaú
Clinical trial register · Brazil

Clinical Trials in Jaú, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Brazil and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2233 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:18 UTC
2233
Studies in scope
all four open statuses
1129
Recruiting now
open to new participants
355
Lead sponsors
across recruiting studies
Top sites
São Paulo 1203 Porto Alegre 891 Rio de Janeiro 472 Curitiba 432 Salvador 347
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC14 AstraZeneca12 Takeda6 Hoffmann-La Roche5 Daiichi Sankyo5 Seagen, a wholly owned subsidiary of Pfizer4 Genmab3 Pfizer3 Merck Sharp & Dohme LLC3 Astellas Pharma Global Development, Inc.2 Exelixis2 Celgene2 Amgen2 Regeneron Pharmaceuticals2 Gilead Sciences2 Taiho Oncology, Inc.1 Latin American Cooperative Oncology Group1 mAbxience Research S.L.1 Bayer1 Hospital Municipal São José1 Abivax S.A.1 Eli Lilly and Company1 Loxo Oncology, Inc.1 Agenus Inc.1 Pierre Fabre Medicament1 Show all 35
Site location
São Paulo1203 Porto Alegre891 Rio de Janeiro472 Curitiba432 Salvador347 Belo Horizonte339 Barretos264 Brasília246 Fortaleza231 Natal215 Campinas197 São José do Rio Preto195 Ribeirão Preto182 Goiânia157 Recife153 Santo André130 Vitória114 Florianópolis108 Ijuí95 Jaú86 Botucatu85 Blumenau73 Joinville68 Passo Fundo63 Belém60 Show all 303
All 303 locations
Target enrolment
to

Trials with a site in Jaú

87 of 2233 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Brazil
Start
Recruiting
AstraZeneca
Phase 3
950
Fortaleza, Itajaí, Jaú, Natal, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
2026-09-16
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Vitória, Goiânia, Ijuí, Pelotas, Bauru, Jaú, São Paulo
2026-09-11
Recruiting
Takeda
Phase 3
324
Rio de Janeiro, Porto Alegre, Florianópolis, Joinville, Jaú, São Paulo
2026-09-10
Recruiting
Hoffmann-La Roche
Phase 3
100
Porto Alegre, Jaú, São Paulo
2026-08-18
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Botucatu, Curitiba, Jaú, Natal, Niterói, Porto Alegre, Ribeirão Preto, Santo André
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Botucatu, Brasília, Curitiba, Jaú, Juiz de Fora, Macaé, Natal, Niterói
2026-05-22
Recruiting
Takeda
Phase 3
300
Salvador, Porto Alegre, Joinville, Jaú, Santos, São Paulo
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 3
100
Porto Alegre, Jaú, São Paulo
2026-04-15
Recruiting
mAbxience Research S.L.
Phase 3
632
Barretos, Belo Horizonte, Bento Gonçalves, Blumenau, Caxias do Sul, Ijuí, Jaú, Lajeado
2025-12-29
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Jaú, Natal, Porto Alegre, São José do Rio Preto, São Paulo, Vitória
2025-12-03
Recruiting
Syndax Pharmaceuticals
Phase 3
468
São Paulo, Fortaleza, Barretos, Jaú, Porto Alegre
2025-11-25
Recruiting
University of Sao Paulo
Phase 3
142
Jaú
2025-11-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Belo Horizonte, Botucatu, Brasília, Curitiba, Fortaleza, Jaú, Juiz de Fora, Macaé
2025-10-03
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Belo Horizonte, Botucatu, Brasília, Curitiba, Fortaleza, Jaú, Macaé, Natal
2025-10-01
Recruiting
Genentech, Inc.
Phase 2
224
Fortaleza, Brasília, Belo Horizonte, Curitiba, Porto Alegre, Aracaju, Ja, Santo André
2025-09-29
Recruiting
AstraZeneca
Phase 3
700
Barretos, Cachoeiro de Itapemirim, Curitiba, Jaú, Londrina, Pelotas, Porto Alegre, Recife
2025-08-06
Recruiting
Pfizer
Phase 3
300
Belo Horizonte, Curitiba, Bairro Santa Cecília, Campinas, Jaú, Rio de Janeiro, São Paulo
2025-07-14
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Belo Horizonte, Blumenau, Fortaleza, Jaú, Lages, Porto Alegre, São Caetano do Sul, São José do Rio Preto
2025-05-22
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Barretos, Jaú, Natal, Porto Alegre, Rio de Janeiro, Santo André, São José do Rio Preto, São Paulo
2025-05-15
Recruiting
Hoffmann-La Roche
Phase 3
425
Volta Redonda, Porto Alegre, Aracaju, Jaú, São José do Rio Preto, São Paulo
2025-05-12
Recruiting
Takeda
Phase 3
225
Curitiba, Porto Alegre, Joinville, Jaú, Santo André, São José do Rio Preto, Rio de Janeiro, São Paulo
2025-05-06
Recruiting
Daiichi Sankyo
Phase 3
582
Belo Horizonte, Blumenau, Jaú, Natal, Porto Alegre, Santo André, São José do Rio Preto, São Paulo
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Bragança Paulista, Brasília, Campinas, Chapecó, Curitiba, Jaú, Mossoró, Porto Alegre
2025-03-18
Recruiting
Daiichi Sankyo
Phase 3
726
Brasília, Brazil, Florianópolis, Jaú, Natal, Porto Alegre, Recife, Ribeirão Preto
2025-02-27
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Santa Cecília, Barretos, Belém, Curitiba, Fortaleza, Ijuí, Jaú, Natal
2025-01-28
Recruiting
Takeda
Phase 3
396
Curitiba, Botucatu, Jaú, Santo André, Rio de Janeiro, São Paulo
2025-01-02
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Barretos, Caxias do Sul, Jaú, Porto Alegre, Salvador, São José do Rio Preto, São Paulo, Vitória
2024-12-12
Active, closed
Hoffmann-La Roche
Phase 3
350
Volta Redonda, Porto Alegre, Aracaju, Jaú, São Paulo
2024-12-11
Active, closed
Daiichi Sankyo
Phase 3
700
Belo Horizonte, Botucatu, Campinas, Curitiba, Florianópolis, Fortaleza, Goiânia, Jaú
2024-11-19
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Barretos, Caxias do Sul, Jaú, Porto Alegre, Salvador, Santa Maria, São José do Rio Preto, São Paulo
2024-10-18
Recruiting
Bayer
Phase 3
444
Fortaleza, Brasília, Recife, Natal, Blumenau, Bauru, Jaú, São José do Rio Preto
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Campinas, Jaú, Porto Alegre, Santo André, São José do Rio Preto, São Paulo
2024-08-28
Recruiting
AstraZeneca
Phase 3
788
Cachoeira de Itapemirim, Curitiba, Fortaleza, Goiânia, Jaú, Porto Alegre, Ribeirão Preto, Salvador
2024-08-01
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Natal, Porto Alegre, Porto Alegrev, Barretos, Jaú, São José do Rio Preto, Rio de Janeiro
2024-07-19
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Natal, Barretos, Belo Horizonte, Curitiba, Florianópolis, Jaú, São Paulo
2024-07-09
Active, closed
Exelixis
Phase 2/3
600
Passo Fundo, Porto Alegre, Jaú, Santo André, São José do Rio Preto, Barretos, Curitiba, Recife
2024-06-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Porto Alegre, Botucatu, Campinas, Jaú, Ribeirão Preto, Santo André, São José do Rio Preto, São Paulo
2024-06-05
Recruiting
Daiichi Sankyo
Phase 1/2
680
Porto Alegre, Florianópolis, Barretos, Jaú
2024-04-10
Recruiting
GlaxoSmithKline
Phase 3
864
Barretos, Belo Horizonte, Florianópolis, Ijuí, Jaú, Joinville, Natal, Porto Alegre
2024-03-21
Recruiting
Takeda
Phase 2
268
Brasília, Juiz de Fora, Porto Alegre, Botucatu, Campinas, Jaú, Ribeirão Preto, Santos
2024-03-05
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Ijuí, Porto Alegre, Barretos, Jaú, Santo André, Vila Olímpia, Salvador
2024-02-21
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Belém, Belo Horizonte, Curitiba, Jaú, Porto Alegre, Salvador, Santa Cruz do Sul, São Paulo
2024-02-16
Active, closed
Regeneron Pharmaceuticals
Phase 3
216
Salvador, Brasília, Cascavel, Curitiba, Porto Alegre, Jaú, Rio de Janeiro, São Paulo
2024-02-15
Recruiting
Pfizer
Phase 3
492
Salvador, Niterói, Porto Alegre, Jaú, Ribeirão Preto, São Paulo, SP, Rio de Janeiro
2024-02-08
Active, closed
Genmab
Phase 3
1,095
Brasília, Belo Horizonte, Curitiba, Jaú, Ribeirão Preto, São Paulo, Rio de Janeiro
2024-02-05
Recruiting
Daiichi Sankyo
Phase 3
250
Brasília, Curitiba, Florianópolis, Ijuí, Jaú, Londrina, Riberão Preto, Rio Grande
2023-12-30
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Salvador, Brasília, Cascavel, Curitiba, Porto Alegre, Jaú, Rio de Janeiro, São Paulo
2023-12-28
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Fortaleza, Porto Alegre, Itajaí, Jaú
2023-12-18
Recruiting
Hospital Municipal São José
Phase 2
100
Belém, Curitiba, Florianópolis, Jaú, Joinville
2023-12-01
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Fortaleza, Belo Horizonte, Curitiba, Passo Fundo, Porto Alegre, Jaú, Barretos, Rio de Janeiro
2023-09-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Jaú, São Paulo
2023-08-08
Active, closed
Latin American Cooperative Oncology Group
Observational
64
Manaus, Vitória, Salvador, Belo Horizonte, Curitiba, Porto Alegre, Barretos, Jaú
2023-07-21
Active, closed
Eli Lilly and Company
Phase 3
3,127
Fortaleza, Vitória, Bequimão, Curitiba, Porto Alegre, Campinas, Jaú, São Bernardo do Campo
2023-06-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Curitiba, Jaú, São Paulo, Rio de Janeiro
2023-03-16
Active, closed
Genmab
Phase 3
900
Curitiba, Rio de Janeiro, Jaú, São Paulo
2023-02-08
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Salvador, Brasília, Curitiba, Caxias do Sul, Botucatu, Jaú, Santo André, Santos
2023-01-16
Recruiting
AstraZeneca
Phase 3
3,527
Belo Horizonte, Campinas, Caxias do Sul, Curitiba, Indaiatuba, Jaú, Natal, Niterói
2022-12-13
Active, closed
Agenus Inc.
Phase 2
234
Jaú, Brasília, Ijuí, Porto Alegre, Pouso Alegre, Rio de Janeiro, São Paulo
2022-11-30
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Curitiba, Barra da Tijuca, Rio de Janeiro, Porto Alegre, Barretos, Jaú, Santo André, São José do Rio Preto
2022-10-24
Recruiting
Celgene
Phase 3
810
Salvador, Porto Alegre, Joinville, Jaú, Rio de Janeiro, São Paulo
2022-09-20
Active, closed
Genmab
Phase 3
549
Curitiba, Botucatu, Jaú, São Paulo, Rio de Janeiro
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Botucatu, Brasília, Campinas, Curitiba, Jaú, Juiz de Fora, Porto Alegre, Salvador
2022-09-13
Active, closed
Gilead Sciences
Phase 3
443
Goiânia, Ijuí, Itajaí, Jaú, Porto Alegre, Rio de Janeiro, Salvador, Santo André
2022-07-25
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Belo Horizonte - MG, Botucatu, Brasília, Curitiba, Jaú, Natal, Porto Alegre, Ribeirão Preto
2022-07-22
Active, closed
Celgene
Phase 3
939
Curitiba, Porto Alegre, Barretos, Jaú, São Paulo, Rio de Janeiro
2022-06-23
Active, closed
AstraZeneca
Phase 3
644
Brasília, Curitiba, Goiânia, Jaú, Porto Alegre, Rio de Janeiro, São Paulo
2022-05-16
Active, closed
Pierre Fabre Medicament
Phase 3
815
Salvador, Curitiba, Londrina, Porto Alegre, Santa Cruz do Sul, Florianópolis, Jaú, Santo André
2022-05-02
Active, closed
Pfizer
Phase 3
854
Salvador, Porto Alegre, Jaú, Ribeirão Preto, São Paulo, SP, Rio de Janeiro
2022-03-25
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Fortaleza, Goiânia, Sao Paulo/SP, Londrina, Natal, Porto Alegre, Barretos, Jaú
2022-03-07
Active, closed
AstraZeneca
Phase 3
1,051
Barretos, Belo Horizonte, Florianópolis, Fortaleza, Jaú, Natal, Porto Alegre, Recife
2022-02-07
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Botucatu, Brasília, Campinas, Curitiba, Fortaleza, Jaú, Macaé, Natal
2022-01-19
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Barretos, Belo Horizonte, Fortaleza, Ipatinga, Jaú, Londrina, Porto Alegre, Rio de Janeiro
2021-12-10
Active, closed
Gilead Sciences
Phase 3
603
Fortaleza, Ijuí, Itajaí, Jaú, Porto Alegre, São Paulo
2021-11-17
Active, closed
Amgen
Phase 3
303
Brasília, Goiânia, Porto Alegre, Jaú, Ribeirão Preto, São Jose Do Rio Preto, Rio de Janeiro, São Paulo
2021-11-02
Active, closed
AstraZeneca
Phase 3
732
Itajaí, Jaú, Porto Alegre, Ribeirão Preto, Rio de Janeiro, São Paulo
2021-10-18
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Porto Alegre, Campinas, Jaú
2021-09-23
Active, closed
Amgen
Phase 1/2
181
Brasília, Recife, Porto Alegre, Jaú, Ribeirão Preto, São Paulo
2021-01-04
Active, closed
AstraZeneca
Phase 3
358
Barretos, Fortaleza, Jaú, Porto Alegre, Recife, Rio de Janeiro, Santa Maria, São José do Rio Preto
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Barretos, Belo Horizonte, Curitiba, Fortaleza, Jardim Blumenau, Jaú, Natal, Porto Alegre
2020-12-07
Active, closed
AstraZeneca
Phase 3
1,012
Belém, Belo Horizonte, Florianópolis, Fortaleza, Jaú, Joinville, Porto Alegre, Ribeirão Preto
2020-07-13
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Salvador, Curitiba, Passo Fundo, Porto Alegre, Campinas, Jaú, Ribeirão Preto, Rio de Janeiro
2018-10-04
Active, closed
Exelixis
Phase 3
837
Salvador, Belo Horizonte, Curitiba, Porto Alegre, Barretos, Jaú, São Paulo
2018-06-10
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Blumenau, Botucatu, Brasília, Campinas, Curitiba, Goiânia, Jaú, Juiz de Fora
2018-04-13
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Barretos, Belo Horizonte, Curitiba, Goiânia, Itajaí, Jaú, Natal, Porto Alegre
2018-03-23
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Campinas, Jaú, Rio de Janeiro, São Paulo
2017-06-26
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Porto Alegre, Bahia, Campinas, Jaú, Rio Grande, Santo André
2016-12-22
Active, closed
Hoffmann-La Roche
Phase 3
154
Porto Alegre, Jaú, São Paulo, Sorocaba, Rio de Janeiro
2015-02-02
Rows per page Showing 1–87 of 87
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Brazilian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-brazil/city/ja

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Brazil and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,233 studies in total at the last sync on 12 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 87 of those studies with a site in Jaú.

How many clinical trials are recruiting in Jaú?

44 of the 87 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 43 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jaú), 87 studies
PhaseStudiesRecruitingShare
Phase 3703680.5%
Phase 210511.5%
Phase 2/3424.6%
Phase 1/2212.3%
Observational101.1%

Most active sponsors

Lead sponsors with the most studies (Jaú)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC146
AstraZeneca126
Takeda65
Daiichi Sankyo54
Hoffmann-La Roche53
Seagen, a wholly owned subsidiary of Pfizer41
Genmab30
Merck Sharp & Dohme LLC32
Pfizer32
Amgen20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.